{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:19:08Z","timestamp":1783351148283,"version":"3.54.6"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01407-y","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:04:53Z","timestamp":1783307093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of FOXM1 in tumor immunology: implications for cancer treatment strategies"],"prefix":"10.1007","volume":"39","author":[{"given":"Shuping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiange","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"1","key":"1407_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends\u2013an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16\u201327. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0578.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"1407_CR2","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s11427-022-2240-6","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yan Q, Fan C, Mo Y, Wang Y, Li X, et al. Overview and countermeasures of cancer burden in China. Sci China Life Sci. 2023;66(11):2515\u201326. https:\/\/doi.org\/10.1007\/s11427-022-2240-6.","journal-title":"Sci China Life Sci"},{"issue":"1","key":"1407_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57\u201370. https:\/\/doi.org\/10.1016\/s0092-8674(00)81683-9.","journal-title":"Cell"},{"issue":"7","key":"1407_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.clinthera.2016.03.026","volume":"38","author":"J Zugazagoitia","year":"2016","unstructured":"Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551\u201366. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.026.","journal-title":"Clin Ther"},{"issue":"1","key":"1407_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"issue":"2","key":"1407_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7782","key":"1407_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nat. 2019;575(7782):299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1.","journal-title":"Nat"},{"key":"1407_CR8","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476.","journal-title":"Front Immunol"},{"issue":"7637","key":"1407_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nat. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nat"},{"issue":"24","key":"1407_CR10","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.18632\/oncotarget.2998","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqu\u00e9 A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5(24):12472\u2013508. https:\/\/doi.org\/10.18632\/oncotarget.2998.","journal-title":"Oncotarget"},{"issue":"6382","key":"1407_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Sci. 2018;359(6382):1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711.","journal-title":"Sci"},{"issue":"11","key":"1407_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1407_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"4","key":"1407_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1407_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","journal-title":"Cancer Discov"},{"issue":"2","key":"1407_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","volume":"20","author":"P Sharma","year":"2020","unstructured":"Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20(2):75\u20136. https:\/\/doi.org\/10.1038\/s41577-020-0275-8.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1407_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immun. 2020;52(1):17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011.","journal-title":"Immun"},{"issue":"26","key":"1407_CR18","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370. https:\/\/doi.org\/10.1200\/JCO.20.00808.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1407_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365\u201379. https:\/\/doi.org\/10.1038\/nrclinonc.2016.211.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1407_CR20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961\u201373. https:\/\/doi.org\/10.1016\/j.cell.2015.07.056.","journal-title":"Cell"},{"issue":"5","key":"1407_CR21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162(5):974\u201386. https:\/\/doi.org\/10.1016\/j.cell.2015.07.011.","journal-title":"Cell"},{"issue":"8","key":"1407_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341. https:\/\/doi.org\/10.1182\/blood-2016-09-738245.","journal-title":"Blood"},{"issue":"6230","key":"1407_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Sci. 2015;348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172.","journal-title":"Sci"},{"issue":"3","key":"1407_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4161\/cc.10.3.14709","volume":"10","author":"TV Kalin","year":"2011","unstructured":"Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell Cycle. 2011;10(3):396\u2013405. https:\/\/doi.org\/10.4161\/cc.10.3.14709.","journal-title":"Cell Cycle"},{"issue":"29","key":"1407_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202702","volume":"9","author":"H Madhi","year":"2022","unstructured":"Madhi H, Lee JS, Choi YE, Li Y, Kim MH, Choi Y, et al. FOXM1 inhibition enhances the therapeutic outcome of lung cancer immunotherapy by modulating PD-L1 expression and cell proliferation. Adv Sci (Weinh). 2022;9(29):e2202702. https:\/\/doi.org\/10.1002\/advs.202202702.","journal-title":"Adv Sci (Weinh)"},{"key":"1407_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2025.111904","volume":"830","author":"Q Chai","year":"2025","unstructured":"Chai Q, Qi Y, Nie X, Wang H. APOC1, transcriptionally regulated by FOXM1, promotes M2 macrophage polarization and cervical cancer progression. Mutat Res. 2025;830:111904. https:\/\/doi.org\/10.1016\/j.mrfmmm.2025.111904.","journal-title":"Mutat Res"},{"key":"1407_CR27","doi-asserted-by":"publisher","DOI":"10.1266\/ggs.24-00079","author":"T Wang","year":"2025","unstructured":"Wang T, Zhang Y, Liu H, Wu J. FOXM1 derived from triple-negative breast cancer exosomes promotes cancer progression by activating IDO1 transcription in macrophages to suppress ferroptosis and induce M2 polarization of tumor-associated macrophages. Genes Genet Syst. 2025. https:\/\/doi.org\/10.1266\/ggs.24-00079.","journal-title":"Genes Genet Syst"},{"key":"1407_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","volume":"92","author":"MA Khan","year":"2023","unstructured":"Khan MA, Khan P, Ahmad A, Fatima M, Nasser MW. FOXM1: a small fox that makes more tracks for cancer progression and metastasis. Semin Cancer Biol. 2023;92:1\u201315. https:\/\/doi.org\/10.1016\/j.semcancer.2023.03.007.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"1407_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1006\/geno.1997.5065","volume":"46","author":"W Korver","year":"1997","unstructured":"Korver W, Roose J, Heinen K, Weghuis DO, de Bruijn D, van Kessel AG, et al. The human TRIDENT\/HFH-11\/FKHL16 gene: structure, localization, and promoter characterization. Genom. 1997;46(3):435\u201342. https:\/\/doi.org\/10.1006\/geno.1997.5065.","journal-title":"Genom"},{"issue":"6","key":"1407_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/onc.2016.249","volume":"36","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, et al. A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. Oncog. 2017;36(6):807\u201319. https:\/\/doi.org\/10.1038\/onc.2016.249.","journal-title":"Oncog"},{"issue":"1","key":"1407_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12964-018-0266-6","volume":"16","author":"GB Liao","year":"2018","unstructured":"Liao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, et al. Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal. 2018;16(1):57. https:\/\/doi.org\/10.1186\/s12964-018-0266-6.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"1407_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ctrv.2009.11.006","volume":"36","author":"Z Wang","year":"2010","unstructured":"Wang Z, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev. 2010;36(2):151\u20136. https:\/\/doi.org\/10.1016\/j.ctrv.2009.11.006.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"1407_CR33","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/nar\/25.9.1715","volume":"25","author":"W Korver","year":"1997","unstructured":"Korver W, Roose J, Clevers H. The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res. 1997;25(9):1715\u20139. https:\/\/doi.org\/10.1093\/nar\/25.9.1715.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1407_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bbcan.2006.08.006","volume":"1775","author":"J Laoukili","year":"2007","unstructured":"Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta. 2007;1775(1):92\u2013102. https:\/\/doi.org\/10.1016\/j.bbcan.2006.08.006.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"1407_CR35","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.febslet.2006.02.021","volume":"580","author":"JM L\u00fcscher-Firzlaff","year":"2006","unstructured":"L\u00fcscher-Firzlaff JM, Lilischkis R, L\u00fcscher B. Regulation of the transcription factor FOXM1c by Cyclin E\/CDK2. FEBS Lett. 2006;580(7):1716\u201322. https:\/\/doi.org\/10.1016\/j.febslet.2006.02.021.","journal-title":"FEBS Lett"},{"issue":"7","key":"1407_CR36","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1128\/MCB.24.7.2649-2661.2004","volume":"24","author":"ML Major","year":"2004","unstructured":"Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300\/CBP coactivators. Mol Cell Biol. 2004;24(7):2649\u201361. https:\/\/doi.org\/10.1128\/MCB.24.7.2649-2661.2004.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"1407_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ncb1217","volume":"7","author":"J Laoukili","year":"2005","unstructured":"Laoukili J, Kooistra MR, Br\u00e1s A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005;7(2):126\u201336. https:\/\/doi.org\/10.1038\/ncb1217.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"1407_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1101\/gad.1200704","volume":"18","author":"VV Kalinichenko","year":"2004","unstructured":"Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004;18(7):830\u201350. https:\/\/doi.org\/10.1101\/gad.1200704.","journal-title":"Genes Dev"},{"issue":"1","key":"1407_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ydbio.2004.08.022","volume":"276","author":"K Krupczak-Hollis","year":"2004","unstructured":"Krupczak-Hollis K, Wang X, Kalinichenko VV, Gusarova GA, Wang IC, Dennewitz MB, et al. The mouse Forkhead Box m1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. Dev Biol. 2004;276(1):74\u201388. https:\/\/doi.org\/10.1016\/j.ydbio.2004.08.022.","journal-title":"Dev Biol"},{"issue":"26","key":"1407_CR40","doi-asserted-by":"publisher","first-page":"16881","DOI":"10.1073\/pnas.252570299","volume":"99","author":"X Wang","year":"2002","unstructured":"Wang X, Kiyokawa H, Dennewitz MB, Costa RH. The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci USA. 2002;99(26):16881\u20136. https:\/\/doi.org\/10.1073\/pnas.252570299.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"1407_CR41","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1038\/s41388-022-02398-4","volume":"41","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, et al. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. 2022;41(32):3899\u2013911. https:\/\/doi.org\/10.1038\/s41388-022-02398-4.","journal-title":"Oncogene"},{"issue":"12","key":"1407_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785\u201397. https:\/\/doi.org\/10.1038\/s41577-021-00541-y.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1407_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/1078-0432.CCR-12-1588","volume":"19","author":"D Li","year":"2013","unstructured":"Li D, Wei P, Peng Z, Huang C, Tang H, Jia Z, et al. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res. 2013;19(1):62\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1588.","journal-title":"Clin Cancer Res"},{"key":"1407_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12920-015-0126-9","volume":"8","author":"Y Zheng","year":"2015","unstructured":"Zheng Y, Guo J, Zhou J, Lu J, Chen Q, Zhang C, et al. FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion. BMC Med Genom. 2015;8:49. https:\/\/doi.org\/10.1186\/s12920-015-0126-9.","journal-title":"BMC Med Genom"},{"issue":"10","key":"1407_CR45","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/onc.2016.307","volume":"36","author":"DW Chan","year":"2017","unstructured":"Chan DW, Hui WW, Wang JJ, Yung MM, Hui LM, Qin Y, et al. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-\u03b2\/SMAD4 signaling. Oncogene. 2017;36(10):1404\u201316. https:\/\/doi.org\/10.1038\/onc.2016.307.","journal-title":"Oncogene"},{"issue":"3","key":"1407_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4161\/cam.23840","volume":"7","author":"KK Ganguly","year":"2013","unstructured":"Ganguly KK, Pal S, Moulik S, Chatterjee A. Integrins and metastasis. Cell Adh Migr. 2013;7(3):251\u201361. https:\/\/doi.org\/10.4161\/cam.23840.","journal-title":"Cell Adh Migr"},{"issue":"8","key":"1407_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023790","volume":"6","author":"GT Lok","year":"2011","unstructured":"Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, et al. Aberrant activation of ERK\/FOXM1 signaling cascade triggers the cell migration\/invasion in ovarian cancer cells. PLoS ONE. 2011;6(8):e23790. https:\/\/doi.org\/10.1371\/journal.pone.0023790.","journal-title":"PLoS ONE"},{"issue":"2","key":"1407_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7150\/ijbs.10634","volume":"11","author":"P Wei","year":"2015","unstructured":"Wei P, Zhang N, Wang Y, Li D, Wang L, Sun X, et al. FOXM1 promotes lung adenocarcinoma invasion and metastasis by upregulating SNAIL. Int J Biol Sci. 2015;11(2):186\u201398. https:\/\/doi.org\/10.7150\/ijbs.10634.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"1407_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-022-01695-6","volume":"22","author":"P Khan","year":"2023","unstructured":"Khan P, Siddiqui JA, Kshirsagar PG, Venkata RC, Maurya SK, Mirzapoiazova T, et al. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4\/FOXM1\/RRM2 axis. Mol Cancer. 2023;22(1):1. https:\/\/doi.org\/10.1186\/s12943-022-01695-6.","journal-title":"Mol Cancer"},{"issue":"1","key":"1407_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2013.07.004","volume":"340","author":"C Yang","year":"2013","unstructured":"Yang C, Chen H, Tan G, Gao W, Cheng L, Jiang X, et al. FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. Cancer Lett. 2013;340(1):104\u201312. https:\/\/doi.org\/10.1016\/j.canlet.2013.07.004.","journal-title":"Cancer Lett"},{"issue":"2","key":"1407_CR51","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1172\/JCI71104","volume":"124","author":"J Xue","year":"2014","unstructured":"Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, et al. Sustained activation of SMAD3\/SMAD4 by FOXM1 promotes TGF-\u03b2-dependent cancer metastasis. J Clin Invest. 2014;124(2):564\u201379. https:\/\/doi.org\/10.1172\/JCI71104.","journal-title":"J Clin Invest"},{"issue":"1","key":"1407_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s13046-019-1307-8","volume":"38","author":"R Zanin","year":"2019","unstructured":"Zanin R, Pegoraro S, Ros G, Ciani Y, Piazza S, Bossi F, et al. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. J Exp Clin Cancer Res. 2019;38(1):313. https:\/\/doi.org\/10.1186\/s13046-019-1307-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"1407_CR53","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41419-021-04421-0","volume":"12","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Zhao H, Chen Y, Li K, Li T, Chen J, et al. Exosomal long noncoding RNA HOXD-AS1 promotes prostate cancer metastasis via miR-361-5p\/FOXM1 axis. Cell Death Dis. 2021;12(12):1129. https:\/\/doi.org\/10.1038\/s41419-021-04421-0.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1407_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12957-018-1352-3","volume":"16","author":"H Pan","year":"2018","unstructured":"Pan H, Zhu Y, Wei W, Shao S, Rui X. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer. World J Surg Oncol. 2018;16(1):59. https:\/\/doi.org\/10.1186\/s12957-018-1352-3.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"1407_CR55","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10555-021-09979-x","volume":"40","author":"K Patil","year":"2021","unstructured":"Patil K, Khan FB, Akhtar S, Ahmad A, Uddin S. The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance. Cancer Metastasis Rev. 2021;40(3):691\u2013720. https:\/\/doi.org\/10.1007\/s10555-021-09979-x.","journal-title":"Cancer Metastasis Rev"},{"issue":"24","key":"1407_CR56","doi-asserted-by":"publisher","first-page":"16545","DOI":"10.1074\/jbc.M709604200","volume":"283","author":"SK Li","year":"2008","unstructured":"Li SK, Smith DK, Leung WY, Cheung AM, Lam EW, Dimri GP, et al. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J Biol Chem. 2008;283(24):16545\u201353. https:\/\/doi.org\/10.1074\/jbc.M709604200.","journal-title":"J Biol Chem"},{"issue":"5","key":"1407_CR57","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/ijms19051340","volume":"19","author":"J Rieth","year":"2018","unstructured":"Rieth J, Subramanian S. Mechanisms of intrinsic tumor resistance to immunotherapy. Int J Mol Sci. 2018;19(5):1340. https:\/\/doi.org\/10.3390\/ijms19051340.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1407_CR58","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"Suppl","key":"1407_CR59","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185\u201398. https:\/\/doi.org\/10.1016\/j.semcancer.2015.03.004.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"1407_CR60","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111\u201322. https:\/\/doi.org\/10.1080\/21645515.2019.1571892.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"1407_CR61","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","volume":"34","author":"DF McDermott","year":"2016","unstructured":"McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;34(8):833\u201342. https:\/\/doi.org\/10.1200\/JCO.2015.63.7421.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1407_CR62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1504627.","journal-title":"N Engl J Med"},{"issue":"2","key":"1407_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","volume":"5","author":"LL Siu","year":"2019","unstructured":"Siu LL, Even C, Mes\u00eda R, Remenar E, Daste A, Delord JP, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. JAMA Oncol. 2019;5(2):195\u2013203. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4628.","journal-title":"JAMA Oncol"},{"issue":"17","key":"1407_CR64","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26(17):3009\u201325. https:\/\/doi.org\/10.2174\/0929867324666170804143706.","journal-title":"Curr Med Chem"},{"issue":"21","key":"1407_CR65","doi-asserted-by":"publisher","first-page":"8305","DOI":"10.3390\/ijms21218305","volume":"21","author":"N Hosseinkhani","year":"2020","unstructured":"Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K, Baghbanzadeh A, et al. Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? Int J Mol Sci. 2020;21(21):8305. https:\/\/doi.org\/10.3390\/ijms21218305.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1407_CR66","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45. https:\/\/doi.org\/10.1186\/s13045-021-01056-8.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1407_CR67","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1111\/cas.14206","volume":"110","author":"Y Akazawa","year":"2019","unstructured":"Akazawa Y, Hosono A, Yoshikawa T, Kaneda H, Nitani C, Hara J, et al. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: a phase I clinical trial. Cancer Sci. 2019;110(12):3650\u201362. https:\/\/doi.org\/10.1111\/cas.14206.","journal-title":"Cancer Sci"},{"key":"1407_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-025-05322-y","author":"S Du","year":"2025","unstructured":"Du S, Li P, Liu Y, Cai B, Li G, Wang W, et al. FOXM1 upregulation promotes immune escape in gastric cancer through activation of Notch signaling pathway. Mol Cell Biochem. 2025. https:\/\/doi.org\/10.1007\/s11010-025-05322-y.","journal-title":"Mol Cell Biochem"},{"issue":"5521","key":"1407_CR69","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.292.5521.1546","volume":"292","author":"K Kawane","year":"2001","unstructured":"Kawane K, Fukuyama H, Kondoh G, Takeda J, Ohsawa Y, Uchiyama Y, et al. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Sci. 2001;292(5521):1546\u20139. https:\/\/doi.org\/10.1126\/science.292.5521.1546.","journal-title":"Sci"},{"issue":"13","key":"1407_CR70","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995. https:\/\/doi.org\/10.3390\/ijms22136995.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"1407_CR71","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1073\/pnas.0400983101","volume":"101","author":"FA Verreck","year":"2004","unstructured":"Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA. 2004;101(13):4560\u20135. https:\/\/doi.org\/10.1073\/pnas.0400983101.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1407_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","volume":"66","author":"P Allavena","year":"2008","unstructured":"Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1\u20139. https:\/\/doi.org\/10.1016\/j.critrevonc.2007.07.004.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"1407_CR73","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.15252\/embj.201797345","volume":"36","author":"M Cort\u00e9s","year":"2017","unstructured":"Cort\u00e9s M, Sanchez-Moral L, de Barrios O, Fern\u00e1ndez-Ace\u00f1ero MJ, Mart\u00ednez-Campanario MC, et al. Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles. EMBO J. 2017;36(22):3336\u201355. https:\/\/doi.org\/10.15252\/embj.201797345.","journal-title":"EMBO J"},{"issue":"9","key":"1407_CR74","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/cbin.10788","volume":"41","author":"L Zhu","year":"2017","unstructured":"Zhu L, Fu X, Chen X, Han X, Dong P. M2 macrophages induce EMT through the TGF-\u03b2\/Smad2 signaling pathway. Cell Biol Int. 2017;41(9):960\u20138. https:\/\/doi.org\/10.1002\/cbin.10788.","journal-title":"Cell Biol Int"},{"key":"1407_CR75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.gene.2019.04.039","volume":"710","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Mao Z, Sun J. NF-\u03baB inhibitor, BAY11-7082, suppresses M2 tumor-associated macrophage induced EMT potential via miR-30a\/NF-\u03baB\/Snail signaling in bladder cancer cells. Gene. 2019;710:91\u20137. https:\/\/doi.org\/10.1016\/j.gene.2019.04.039.","journal-title":"Gene"},{"issue":"Pt B","key":"1407_CR76","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","volume":"99","author":"Y Komohara","year":"2016","unstructured":"Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2016;99(Pt B):180\u20135. https:\/\/doi.org\/10.1016\/j.addr.2015.11.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"20","key":"1407_CR77","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-13-2347","volume":"74","author":"KH Parker","year":"2014","unstructured":"Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014;74(20):5723\u201333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2347.","journal-title":"Cancer Res"},{"issue":"24","key":"1407_CR78","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","volume":"71","author":"N Obermajer","year":"2011","unstructured":"Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71(24):7463\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2449.","journal-title":"Cancer Res"},{"key":"1407_CR79","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","volume":"5","author":"N Wang","year":"2014","unstructured":"Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1\u2013m2 polarization balance. Front Immunol. 2014;5:614. https:\/\/doi.org\/10.3389\/fimmu.2014.00614.","journal-title":"Front Immunol"},{"issue":"3","key":"1407_CR80","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1568010054022024","volume":"4","author":"N Fujiwara","year":"2005","unstructured":"Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(3):281\u20136. https:\/\/doi.org\/10.2174\/1568010054022024.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"7446","key":"1407_CR81","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nat. 2013;496(7446):445\u201355. https:\/\/doi.org\/10.1038\/nature12034.","journal-title":"Nat"},{"issue":"2","key":"1407_CR82","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cmet.2007.06.010","volume":"6","author":"MA Bouhlel","year":"2007","unstructured":"Bouhlel MA, Derudas B, Rigamonti E, Di\u00e8vart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6(2):137\u201343. https:\/\/doi.org\/10.1016\/j.cmet.2007.06.010.","journal-title":"Cell Metab"},{"issue":"4","key":"1407_CR83","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.smim.2015.08.001","volume":"27","author":"AJ Covarrubias","year":"2015","unstructured":"Covarrubias AJ, Aksoylar HI, Horng T. Control of macrophage metabolism and activation by mTOR and Akt signaling. Semin Immunol. 2015;27(4):286\u201396. https:\/\/doi.org\/10.1016\/j.smim.2015.08.001.","journal-title":"Semin Immunol"},{"key":"1407_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109121","volume":"184","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhang B, Yang Y, Peng B, Ye R. FOXM1 accelerates wound healing in diabetic foot ulcer by inducing M2 macrophage polarization through a mechanism involving SEMA3C\/NRP2\/Hedgehog signaling. Diabetes Res Clin Pract. 2022;184:109121. https:\/\/doi.org\/10.1016\/j.diabres.2021.109121.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"1407_CR85","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"1407_CR86","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41568-020-0259-9","volume":"20","author":"MT Villanueva","year":"2020","unstructured":"Villanueva MT. Macrophages get a CAR. Nat Rev Cancer. 2020;20(6):300. https:\/\/doi.org\/10.1038\/s41568-020-0259-9.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1407_CR87","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13(1):153. https:\/\/doi.org\/10.1186\/s13045-020-00983-2.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1407_CR88","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021;81(5):1201\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2990.","journal-title":"Cancer Res"},{"issue":"5","key":"1407_CR89","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cancers12051075","volume":"12","author":"S Kailayangiri","year":"2020","unstructured":"Kailayangiri S, Altvater B, Wiebel M, Jamitzky S, Rossig C. Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers (Basel). 2020;12(5):1075. https:\/\/doi.org\/10.3390\/cancers12051075.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1407_CR90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li N, Geng S, Dong ZZ, Jin Y, Ying H, Li HW, et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23(1):117. https:\/\/doi.org\/10.1186\/s12943-024-02032-9.","journal-title":"Mol Cancer"},{"issue":"3","key":"1407_CR91","doi-asserted-by":"publisher","first-page":"333","DOI":"10.20892\/j.issn.2095-3941.2021.0087","volume":"19","author":"H Guo","year":"2021","unstructured":"Guo H, Qian L, Cui J. Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome. Cancer Biol Med. 2021;19(3):333\u201342. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2021.0087.","journal-title":"Cancer Biol Med"},{"issue":"5","key":"1407_CR92","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1007\/s11010-024-05170-2","volume":"480","author":"H Gao","year":"2025","unstructured":"Gao H, Shi L, Liu J, Zhao Y, Du F, He Y, et al. FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner. Mol Cell Biochem. 2025;480(5):3051\u201366. https:\/\/doi.org\/10.1007\/s11010-024-05170-2.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"1407_CR93","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang C, Jiang A, Lin A, Liu Z, Cheng X, et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Transl Med. 2024;22(1):293. https:\/\/doi.org\/10.1186\/s12967-024-05104-y.","journal-title":"J Transl Med"},{"issue":"5","key":"1407_CR94","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","volume":"15","author":"HM Knochelmann","year":"2018","unstructured":"Knochelmann HM, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann JM, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458\u201369. https:\/\/doi.org\/10.1038\/s41423-018-0004-4.","journal-title":"Cell Mol Immunol"},{"key":"1407_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34083","author":"RR Malla","year":"2022","unstructured":"Malla RR, Vasudevaraju P, Vempati RK, Rakshmitha M, Merchant N, Nagaraju GP. <article-title update=\"added\">Weekly cisplatin with or without imatinib in advanced chordoma: a retrospective case\u2010series analysis from the Italian Rare Cancers Network. Cancer. 2022. https:\/\/doi.org\/10.1002\/cncr.34083.","journal-title":"Cancer"},{"issue":"16","key":"1407_CR96","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081.","journal-title":"Curr Biol"},{"issue":"1","key":"1407_CR97","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023;8(1):235. https:\/\/doi.org\/10.1038\/s41392-023-01471-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1407_CR98","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/1878-0261.12443","volume":"13","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Chen H, Xie R, Wang H, Li S, Xu Q, et al. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer. Mol Oncol. 2019;13(4):873\u201393. https:\/\/doi.org\/10.1002\/1878-0261.12443.","journal-title":"Mol Oncol"},{"issue":"2","key":"1407_CR99","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41419-024-06488-x","volume":"15","author":"B Ziman","year":"2024","unstructured":"Ziman B, Yang Q, Zheng Y, Sheth M, Nam C, Zhao H, et al. Epigenomic analyses identify FOXM1 as a key regulator of anti-tumor immune response in esophageal adenocarcinoma. Cell Death Dis. 2024;15(2):152. https:\/\/doi.org\/10.1038\/s41419-024-06488-x.","journal-title":"Cell Death Dis"},{"key":"1407_CR100","doi-asserted-by":"publisher","first-page":"1138524","DOI":"10.3389\/fimmu.2023.1138524","volume":"14","author":"Z Xu","year":"2023","unstructured":"Xu Z, Pei C, Cheng H, Song K, Yang J, Li Y, et al. Comprehensive analysis of FOXM1 immune infiltrates, m6a, glycolysis and ceRNA network in human hepatocellular carcinoma. Front Immunol. 2023;14:1138524. https:\/\/doi.org\/10.3389\/fimmu.2023.1138524.","journal-title":"Front Immunol"},{"issue":"2","key":"1407_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009229","volume":"5","author":"L Xue","year":"2010","unstructured":"Xue L, Chiang L, He B, Zhao YY, Winoto A. FoxM1, a forkhead transcription factor is a master cell cycle regulator for mouse mature T cells but not double positive thymocytes. PLoS ONE. 2010;5(2):e9229. https:\/\/doi.org\/10.1371\/journal.pone.0009229.","journal-title":"PLoS ONE"},{"issue":"1","key":"1407_CR102","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"issue":"1","key":"1407_CR103","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cells10010014","volume":"10","author":"M Pellegrino","year":"2020","unstructured":"Pellegrino M, Del Bufalo F, De Angelis B, Quintarelli C, Caruana I, de Billy E. Manipulating the metabolism to improve the efficacy of CAR T-cell immunotherapy. Cells. 2020;10(1):14. https:\/\/doi.org\/10.3390\/cells10010014.","journal-title":"Cells"},{"issue":"3","key":"1407_CR104","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/0008-5472.CAN-19-1196","volume":"80","author":"T Kondo","year":"2020","unstructured":"Kondo T, Ando M, Nagai N, Tomisato W, Srirat T, Liu B, et al. The NOTCH-FOXM1 axis plays a key role in mitochondrial biogenesis in the induction of human stem cell memory-like CAR-T cells. Cancer Res. 2020;80(3):471\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1196.","journal-title":"Cancer Res"},{"issue":"5","key":"1407_CR105","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375\u201386. https:\/\/doi.org\/10.1038\/nri1604.","journal-title":"Nat Rev Immunol"},{"issue":"45","key":"1407_CR106","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaz2738","volume":"5","author":"CJ Nicolai","year":"2020","unstructured":"Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO, et al. NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists. Sci Immunol. 2020;5(45):eaaz2738. https:\/\/doi.org\/10.1126\/sciimmunol.aaz2738.","journal-title":"Sci Immunol"},{"issue":"4","key":"1407_CR107","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immun. 2018;49(4):754-763.e4. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.016.","journal-title":"Immun"},{"issue":"5","key":"1407_CR108","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3390\/ijms22052608","volume":"22","author":"R Ahn","year":"2021","unstructured":"Ahn R, Ursini-Siegel J. Clinical potential of kinase inhibitors in combination with immune checkpoint inhibitors for the treatment of solid tumors. Int J Mol Sci. 2021;22(5):2608. https:\/\/doi.org\/10.3390\/ijms22052608.","journal-title":"Int J Mol Sci"},{"key":"1407_CR109","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cyto.2015.11.011","volume":"89","author":"K Meissl","year":"2017","unstructured":"Meissl K, Macho-Maschler S, M\u00fcller M, Strobl B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 2017;89:12\u201320. https:\/\/doi.org\/10.1016\/j.cyto.2015.11.011.","journal-title":"Cytokine"},{"issue":"10","key":"1407_CR110","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142\u20139. https:\/\/doi.org\/10.1038\/ni.3558.","journal-title":"Nat Immunol"},{"issue":"7676","key":"1407_CR111","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature24050","volume":"550","author":"Z Dou","year":"2017","unstructured":"Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nat. 2017;550(7676):402\u20136. https:\/\/doi.org\/10.1038\/nature24050.","journal-title":"Nat"},{"issue":"9","key":"1407_CR112","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ncb3586","volume":"19","author":"S Gl\u00fcck","year":"2017","unstructured":"Gl\u00fcck S, Guey B, Gulen MF, Wolter K, Kang TW, Schmacke NA, et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. Nat Cell Biol. 2017;19(9):1061\u201370. https:\/\/doi.org\/10.1038\/ncb3586.","journal-title":"Nat Cell Biol"},{"issue":"23","key":"1407_CR113","doi-asserted-by":"publisher","first-page":"E4612","DOI":"10.1073\/pnas.1705499114","volume":"114","author":"H Yang","year":"2017","unstructured":"Yang H, Wang H, Ren J, Chen Q, Chen ZJ. cGAS is essential for cellular senescence. Proc Natl Acad Sci USA. 2017;114(23):E4612\u201320. https:\/\/doi.org\/10.1073\/pnas.1705499114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1407_CR114","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","volume":"33","author":"EN Chin","year":"2023","unstructured":"Chin EN, Sulpizio A, Lairson LL. Targeting STING to promote antitumor immunity. Trends Cell Biol. 2023;33(3):189\u2013203. https:\/\/doi.org\/10.1016\/j.tcb.2022.06.010.","journal-title":"Trends Cell Biol"},{"issue":"4","key":"1407_CR115","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1111\/jcmm.15948","volume":"25","author":"H Xie","year":"2021","unstructured":"Xie H, Miao N, Xu D, Zhou Z, Ni J, Yin F, et al. FOXM1 promotes Wnt\/\u03b2-catenin pathway activation and renal fibrosis via transcriptionally regulating multi-Wnts expressions. J Cell Mol Med. 2021;25(4):1958\u201371. https:\/\/doi.org\/10.1111\/jcmm.15948.","journal-title":"J Cell Mol Med"},{"key":"1407_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6165","volume":"5","author":"MV Gormally","year":"2014","unstructured":"Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014;5:5165. https:\/\/doi.org\/10.1038\/ncomms6165.","journal-title":"Nat Commun"},{"key":"1407_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0141-7","volume":"5","author":"Y Ziegler","year":"2019","unstructured":"Ziegler Y, Laws MJ, Sanabria Guillen V, Kim SH, Dey P, Smith BP, et al. Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds. NPJ Breast Cancer. 2019;5:45. https:\/\/doi.org\/10.1038\/s41523-019-0141-7.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1407_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01421-4","volume":"17","author":"C Liu","year":"2024","unstructured":"Liu C, Vorderbruggen M, Mu\u00f1oz-Trujillo C, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, et al. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells. J Ovarian Res. 2024;17(1):94. https:\/\/doi.org\/10.1186\/s13048-024-01421-4.","journal-title":"J Ovarian Res"},{"issue":"24","key":"1407_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246282","volume":"13","author":"Y Ziegler","year":"2021","unstructured":"Ziegler Y, Guillen VS, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS. Transcription regulation and genome rewiring governing sensitivity and resistance to FOXM1 inhibition in breast cancer. Cancers (Basel). 2021;13(24):6282. https:\/\/doi.org\/10.3390\/cancers13246282.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1407_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06056-9","volume":"14","author":"H Bu","year":"2023","unstructured":"Bu H, Lan X, Cheng H, Pei C, Ouyang M, Chen Y, et al. Development of an interfering peptide M1-20 with potent anti-cancer effects by targeting FOXM1. Cell Death Dis. 2023;14(8):533. https:\/\/doi.org\/10.1038\/s41419-023-06056-9.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1407_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01059-7","volume":"13","author":"H Cheng","year":"2023","unstructured":"Cheng H, Yuan J, Pei C, Ouyang M, Bu H, Chen Y, et al. The development of an anti-cancer peptide M1-21 targeting transcription factor FOXM1. Cell Biosci. 2023;13(1):114. https:\/\/doi.org\/10.1186\/s13578-023-01059-7.","journal-title":"Cell Biosci"},{"issue":"17","key":"1407_CR122","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/onc.2015.282","volume":"35","author":"F Kruiswijk","year":"2016","unstructured":"Kruiswijk F, Hasenfuss SC, Sivapatham R, Baar MP, Putavet D, et al. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene. 2016;35(17):2166\u201377. https:\/\/doi.org\/10.1038\/onc.2015.282.","journal-title":"Oncogene"},{"issue":"1","key":"1407_CR123","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13058-023-01675-8","volume":"25","author":"BS Katzenellenbogen","year":"2023","unstructured":"Katzenellenbogen BS, Guillen VS, Katzenellenbogen JA. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer. Breast Cancer Res. 2023;25(1):76. https:\/\/doi.org\/10.1186\/s13058-023-01675-8.","journal-title":"Breast Cancer Res"},{"key":"1407_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218160","volume":"638","author":"MA Khan","year":"2026","unstructured":"Khan MA, Khan P, Fatima M, Nasser MW. Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. Cancer Lett. 2026;638:218160. https:\/\/doi.org\/10.1016\/j.canlet.2025.218160.","journal-title":"Cancer Lett"},{"key":"1407_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08421-w","author":"F Xie","year":"2025","unstructured":"Xie F, Zhou X, Ran Y, Li R, Zou J, Wan S, et al. Targeting FOXM1 condensates reduces breast tumour growth and metastasis. Nat. 2025. https:\/\/doi.org\/10.1038\/s41586-024-08421-w.","journal-title":"Nat"},{"issue":"12","key":"1407_CR126","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1158\/0008-5472.CAN-10-0545","volume":"70","author":"JR Carr","year":"2010","unstructured":"Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res. 2010;70(12):5054\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0545.","journal-title":"Cancer Res"},{"issue":"5","key":"1407_CR127","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/jcmm.12216","volume":"18","author":"X Li","year":"2014","unstructured":"Li X, Yao R, Yue L, Qiu W, Qi W, Liu S, et al. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J Cell Mol Med. 2014;18(5):811\u201323. https:\/\/doi.org\/10.1111\/jcmm.12216.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"1407_CR128","doi-asserted-by":"publisher","first-page":"8574","DOI":"10.18632\/oncotarget.14351","volume":"8","author":"T Xie","year":"2017","unstructured":"Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, et al. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget. 2017;8(5):8574\u201389. https:\/\/doi.org\/10.18632\/oncotarget.14351.","journal-title":"Oncotarget"},{"key":"1407_CR129","doi-asserted-by":"publisher","first-page":"638","DOI":"10.18632\/oncotarget.28650","volume":"15","author":"JJ Lingo","year":"2024","unstructured":"Lingo JJ, Voigt E, Quelle DE. Linking FOXM1 and PD-L1 to CDK4\/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors. Oncotarget. 2024;15:638\u201343. https:\/\/doi.org\/10.18632\/oncotarget.28650.","journal-title":"Oncotarget"},{"issue":"23","key":"1407_CR130","doi-asserted-by":"publisher","first-page":"24424","DOI":"10.18632\/aging.202300","volume":"12","author":"Y Yang","year":"2020","unstructured":"Yang Y, Jiang H, Li W, Chen L, Zhu W, Xian Y, et al. FOXM1\/DVL2\/Snail axis drives metastasis and chemoresistance of colorectal cancer. Aging (Albany NY). 2020;12(23):24424\u201340. https:\/\/doi.org\/10.18632\/aging.202300.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"1407_CR131","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","volume":"13","author":"X Li","year":"2020","unstructured":"Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020;13(1):50. https:\/\/doi.org\/10.1186\/s13045-020-00885-3.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1407_CR132","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","volume":"41","author":"K Wang","year":"2022","unstructured":"Wang K, Dai X, Yu A, Feng C, Liu K, Huang L. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression. J Exp Clin Cancer Res. 2022;41(1):289. https:\/\/doi.org\/10.1186\/s13046-022-02483-2.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01407-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:02:58Z","timestamp":1783350178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01407-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":132,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01407-y","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"100"}}